Combination Strategies for Immune Checkpoint Inhibitors in PBRM1-mutant Renal Cell Carcinoma: To PARP or Not To PARP?
- PMID: 34753637
- DOI: 10.1016/j.eururo.2021.10.028
Combination Strategies for Immune Checkpoint Inhibitors in PBRM1-mutant Renal Cell Carcinoma: To PARP or Not To PARP?
Comment on
-
The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.Eur Urol. 2022 Feb;81(2):145-148. doi: 10.1016/j.eururo.2021.09.024. Epub 2021 Oct 6. Eur Urol. 2022. PMID: 34627641
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
